Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report)
Adeiza M, Kekulah I, Wachekwa I, Ogbuagu O. Dolutegravir hypersensitivity reaction: the need for strengthening pharmacovigilance systems with optimization of antiretroviral therapy in HIV programs in resource-limited settings (case report). PAMJ Clinical Medicine 2022, 8 DOI: 10.11604/pamj-cm.2022.8.47.33930.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAdverse drug reactionsDrug reactionsHIV programsResource-limited settingsAntiretroviral therapyHypersensitivity reactionsAdvanced HIV diseaseLamivudine/tenofovirLamivudine/zidovudineRoutine laboratory monitoringCombination antiretroviral therapyAntiretroviral drug treatmentFirst-line cARTFeatures of anaphylaxisRelevant health educationDrug discontinuityViral suppressionHIV diseaseHIV infectionBlood workOpportunistic infectionsLaboratory monitoringNew symptomsDrug treatmentMedical treatment